• In the first quarter of 2026, Repligen Corporation reported revenue of US$194.26 million and net income of US$8.33 million, both higher than a year earlier, and raised its full-year adjusted earnings guidance while slightly trimming its revenue outlook.
• These results reflected broad growth across key product lines, early benefits from a margin-focused restructuring program, and the impact of divesting the non-core Polymem filtration business.
• We’ll now examine how Repligen’s higher full-year profit guidance, despite softer revenue expectations, influences its existing investment narrative.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Repligen Investment Narrative Recap

To own Repligen, you need to believe that its bioprocessing tools can keep gaining share even as biotech funding and modality trends stay uneven. Right now, the key near term catalyst is management’s margin expansion effort, and Q1’s stronger profits and higher full year EPS guidance support that focus. The biggest current risk remains demand volatility from smaller biotech customers and specific modalities; this quarter’s results do not remove that uncertainty.

The Q1 2026 earnings update is the most relevant development here. Repligen raised its adjusted EPS guidance midpoint to about US$2.01 while trimming revenue expectations, reflecting cost discipline, the Polymem divestiture, and the new Transformation Office. For investors watching catalysts, that combination puts more emphasis on execution around margins and less on pure top line acceleration, at least over the next few quarters.

Yet behind the stronger EPS outlook, investors should be aware that revenue visibility for smaller biotech customers remains...

Repligen's narrative projects $1.1 billion revenue and $130.3 million earnings by 2029.

Uncover how Repligen's forecasts yield a $183.88 fair value, a 49% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were assuming revenue of about US$1.1 billion and earnings near US$119 million by 2029, so this profit focused quarter may or may not soften their concerns about customer concentration and macro risks.

Explore 3 other fair value estimates on Repligen - why the stock might be worth as much as 49% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Repligen research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Repligen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Repligen's overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.